SANTRAL DEV HÜCRELİ GRANÜLOMLARDA GEÇMİŞTEN GÜNÜMÜZE TEDAVİ YÖNTEMLERİ

Yıl 2024, , 238 - 246, 26.01.2024

Ilgın Arı , Arzum Yılmaz , Alper Aktaş

https://doi.org/10.54617/adoklinikbilimler.1334729

Öz

Santral dev hücreli granülomlar (SDHG), çene kemiklerinde oldukça nadir görülen lezyonlardır. Geçmişten günümüze pek çok farklı isimlendirmeleri vardır ve etyolojileri hala net olarak bilinmemektedir. Radyolojik ve klinik özellikle açısından ameloblastoma, miksoma, cherubizm, anevrizmal kemik kisti vs. lezyonlarla ayırıcı tanısının yapılması gerekir. Ancak tanı koyulduktan sonra dahi uygun tedavi yönteminin seçilmesi her zaman kolay olmayabilir. Literatürde en çok bilinen ve uygulanan tedavi yöntemi küretaj olsa da agresif tipte seyreden lezyonlarda bu tedavi şekli nüks ve çene kemiklerinde ileri düzey defektlerle sonuçlanabilir. Bu sebepten dolayı intralezyonal steroid enjeksiyonu, denasumab, tirozin-kinaz inhibitörü, kalsitonin uygulamaları gibi tedavi seçenekleri geliştirilmiştir. Ancak optimal tedavi algoritması henüz tanımlanmamıştır. Bu derlemenin amacı; mevcut tedavi seçeneklerinin uygulama şekilleri, dozları, güncel literatürdeki vaka raporları ve çalışma sonuçları hakkında bilgi vermektir.

Anahtar Kelimeler

Alternatif tedavi seçenekleri, Nüks, Santral dev hücreli granülom

THE CURRENT TREATMENT METHODS IN CENTRAL GIANT CELL GRANULOMAS

Öz

Central giant cell granulomas (SDHG) are extremely rare lesions in the jaw bones. It has many different identifications from past to present, and their etiology is still not clearly known. In terms of radiological and clinical features, differential diagnosis should be made with lesions such as ameloblastoma, myxoma, cherubism, aneurysmal bone cyst etc. However, even after the diagnosis is made, it is not always easy to choose the appropriate treatment method. Although curettage is the most known and applied treatment method in the literature, this type of treatment may result in recurrence and advanced defects in the jaw bones in aggressive lesions. For this reason, different treatment options such as intralesional steroid injection, denasumab, tyrosine-kinase inhibitor, calcitonin applications have been developed. However, the optimal treatment algorithm has not yet been defined. The aim of this review was to investigate information about the application methods, doses of treatment methods and presented case reports and studies in the current literature.

Anahtar Kelimeler

Central giant cell granloma, Recurrence, Treatment options

Kaynakça

• Referans1. Neville B, Damm D, Chi A, Allen C. Oral and maxillofacial pathology 4th edition. St Louis, MO, Westline Industrial Dr: Elsevier Health Sciences 2015.
• Referans2. Jaffe HL. Giant-cell reparative granuloma, traumatic bone cyst, and fibrous (fibro-osseous) dysplasia of the jawbones. Oral Surg Oral Med Oral Pathol 1953;6:159-75.
• Referans3. De Lange J, Van den Akker HP. Clinical and radiological features of central giant-cell lesions of the jaw.Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;99:464-70.
• Referans4. Miloro M, Ghali G, Larsen PE, Waite PD. Peterson’s principles of oral and maxillofacial surgery: Springer; 2004.
• Referans5. Kransdorf M, Moser Jr R, Gilkey F. Fibrous dysplasia. Radiographics 1990;10:519-37.
• Referans6. Mendenhall WM, Werning JW, Fernandes R, Malyapa RS, Mendenhall NP. Ameloblastoma. Am J Clin Oncol 2007;30:645-8.
• Referans7. Barros RE, Dominguez FV, Cabrini RL. Myxoma of the jaws. Oral Surg Oral Med Oral Pathol 1969;27:225-36.
• Referans8. Hansen LS, Sapone J, Sproat RC. Traumatic bone cysts of jaws: report of sixty-six cases. Oral Surg Oral Med Oral Pathol 1974;37:899-910.
• Referans9. Papadaki ME, Lietman SA, Levine MA, Olsen BR, Kaban LB, Reichenberger EJ. Cherubism: best clinical practice. Orphanet J Rare Dis 2012;7:1-14.
• Referans10. Chew FS, Huang-Hellinger F. Brown tumor. AJR Am J Roentgenol 1993;160:752.
• Referans11. Flanagan AM, Tinkler SM, Horton M, Williams D, Chambers T. The multinucleate cells in giant cell granulomas of the jaw are osteoclasts. Cancer 1988;62:1139-45.
• Referans12. Kaban LB, Troulis MJ, Ebb D, August M, Hornicek FJ, Dodson TB. Antiangiogenic therapy with interferon alpha for giant cell lesions of the jaws. J Oral Maxillofac Surg 2002;60:1103-11.
• Referans13. Chuong R, Kaban LB, Kozakewich H, Perez-Atayde A. Central giant cell lesions of the jaws: a clinicopathologic study. J Oral Maxillofac Surg 1986;44:708-13.
• Referans14. Kaban LB, Mulliken JB, Ezekowitz RA, Phil D, Ebb D, Smith PS, et al. Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a. Pediatrics 1999;103:1145-9.
• Referans15. Gomes CC, Gayden T, Bajic A, Harraz OF, Pratt J, Nikbakht H, et al. TRPV4 and KRAS and FGFR1 gain-of-function mutations drive giant cell lesions of the jaw. Nat Commun 2018;9:4572.
• Referans16. Kudva A, Cariappa K, Dhara V, Solomon M. Central giant cell granuloma: An uncommon presentation. Oral and Maxillofacial Surgery Cases 2018;4:135-40.
• Referans17. Chrcanovic BR, Gomes CC, Dos Santos TR, Abreu MHNG, Gomez RS. Clinical factors associated with the recurrence of central giant cell lesions. J Oral Pathol Med 2019;48:799-802.
• Referans18. Lee H, Ercoli C, Fantuzzo JJ, Girotto JA, Coniglio JU, Palermo M. Oral rehabilitation of a 12-year-old patient diagnosed with a central giant cell granuloma using a fibula graft and an implant-supported prosthesis: a clinical report. J Prosthet Dent 2008;99:257-62.
• Referans19. Neville BW, Damm DD, Allen CM, Chi AC. Oral and maxillofacial pathology: Elsevier Health Sciences; 2015.
• Referans20. Bredell M, Rordorf T, Kroiss S, Rücker M, Zweifel DF, Rostetter C. Denosumab as a treatment alternative for central giant cell granuloma: a long-term retrospective cohort study. J Oral Maxillofac Surg 2018;76:775-84.
• Referans21. de Mendonça RP, Mitre GP, Real FH, da Silva Kataoka MS, de Melo Alves Júnior S, Vianna P, et al. Central giant cell granuloma treated with intralesional corticosteroid injections and bisphosphonates: a long-term follow-up case study. Head Neck Pathol 2020;14:497-502.
• Referans22. Cavalcante IL, Barros CCS, Rodrigues KA, Osterne RL, Cavalcante RB, Nogueira RM, et al. Quantification of bone gain in central giant cell granuloma of the jaws submitted to intralesional corticotherapy. J Bras Patol Med Lab 2018;54:183-8.
• Referans23. Miguita L, de Souza JC, Bastos VC, Pereira NB, de Freitas RAB, Guimarães LM, et al. Central giant cell granulomas of the jaws stromal cells harbour mutations and have osteogenic differentiation capacity, in vivo and in vitro. J Oral Pathol Med 2022;51:206-16.
• Referans24. Camarini C, de Souza Tolentino E. Non-surgical treatment as an alternative for the management of central giant cell granuloma: A systematic review. Clin Oral Investig 2022:1-22.
• Referans25. Hirayama T, Sabokbar A, Athanasou N. Effect of corticosteroids on human osteoclast formation and activity. J Endocrinol 2002;175:155-64.
• Referans26. Jacoway J. Central giant cell granuloma-an alternative to surgical therapy. Oral Surg Oral Med Oral Pathol 1988;66:572.
• Referans27. Dolanmaz D, Esen A, Mihmanlı A, Işık K. Management of central giant cell granuloma of the jaws with intralesional steroid injection and review of the literature. Oral Maxillofac Surg 2016;20:203-9.
• Referans28. Mukdad M, Barut O, Sjöström M. Intralesional corticosteroid injections as first option for management of giant cell lesion of the lower jaw in a 56-year-old patient: A case report and brief literature review. Oral and Maxillofacial Surgery Cases 2022;8:100283.
• Referans29. Carlos R, Sedano HO. Intralesional corticosteroids as an alternative treatment for central giant cell granuloma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;93:161-6.
• Referans30. Joshi S, Koranne V, Pawar S, Pawar P, Lakhani K, Salema H. Conservative Management of Central Giant Cell Granuloma-A Case Report. Journal of Indian Academy of Oral Medicine and Radiology 2023;35:141-3.
• Referans31. El Hadidi YN, Ghanem AA, Helmy I. Injection of steroids intralesional in central giant cell granuloma cases (giant celltumor): Is it free of systemic complications or not? A case report. Int J Surg Case Rep 2015;8:166-70.
• Referans32. Harris M. Central giant cell granulomas of the jaws regress with calcitonin therapy. Br J Oral Maxillofac Surg 1993;31:89-94.
• Referans33. Allon DM, Anavi Y, Calderon S. Central giant cell lesion of the jaw: nonsurgical treatment with calcitonin nasal spray. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;107:811-8.
• Referans34. Pogrel AM. The diagnosis and management of giant cell lesions of the jaws. Ann Maxillofac Surg 2012;2:102.
• Referans35. de Lange J, van den Akker HP, Veldhuijzen van Zanten GO, Engelshove HA, van den Berg H, Klip H. Calcitonin therapy in central giant cell granuloma of the jaw: a randomized double-blind placebo-controlled study. Int J Oral Maxillofac Surg 2006;35:791-5.
• Referans36. Pageau SC, editor Denosumab. MAbs; 2009: Taylor & Francis.
• Referans37. Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay J-Y, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010;11:275-80.
• Referans38. Gupta B, Stanton N, Coleman H, White C, Singh J. A novel approach to the management of a central giant cell granuloma with denosumab: a case report and review of current treatments. J Craniomaxillofac Surg 2015;43:1127-32.
• Referans39. Schreuder WH, Coumou AW, Kessler PA, de Lange J. Alternative pharmacologic therapy for aggressive central giant cell granuloma: denosumab. J Oral Maxillofac Surg 2014;72:1301-9.
• Referans40. Pogrel M, Hossaini-Zadeh M. Denosumab for the management of central giant cell granuloma of the jaws—a case series. Int J Oral Maxillofac Surg 2021;50:1019-22.
• Referans41. Amorós CM, Bascones AE, Leone RC, De la Sen Corcuera Ó, Barone S, Marina MDP. Central giant cell granuloma: off-label treatment with Denosumab in a patient with Noonan syndrome. J Stomatol Oral Maxillofac Surg 2023:101640.
• Referans42. Choe M, Smith V, Okcu MF, Wulff J, Gruner S, Huisman TA, et al. Treatment of central giant cell granuloma in children with denosumab. Pediatr Blood Cancer 2021;68:e28778.
• Referans43. Tallent B, Padilla RJ, McKay C, Foreman AKM, Fan Z, Blatt J. Response of central giant cell granuloma of the jaw to imatinib. J Pediatr Hematol Oncol 2023;45:278-80.
• Referans44. de Lange J, van Rijn RR, van den Berg H, van den Akker HP. Regression of central giant cell granuloma by a combination of imatinib and interferon: a case report. Br J Oral Maxillofac Surg 2009;47:59-61.
• Referans45. Posner I, Engel M, Gazit A, Levitzki A. Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program. Mol Pharmacol 1994;45:673-83.